multiple myeloma
Conditions
Interventions
Bortezomib 1.3mg/m2 iv., day1, 8, 15, and 22. 6 courses in 35-day cycle.
Sponsors
University Of Tokyo Hospital, Department of Hematology and Oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with multiple myeloma who have received autologous hematopoietic stem cell transplantation for the first time within 3 months.(Including patients who are planed to recieve autologous stem cell transplanation.) 2. Meet the guideline for administaration of Bortezmib at the start of the study treatment. 3. Clinical data at disease onset and before transplantation can be obtaioned. 4. Maintanance therapy can be started by 4 months after transplantation. 5. Written-informed consent has obtained.
Exclusion criteria
Exclusion criteria: 1. Allergy for Bortezomib, mannitol, and boron. 2. A woman during pregnancy or potential pregnancy. 3. Patients who cannot stop drugs or therapy restricted in this trial. 4. Patients who are recoginized as inadaptable for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate 1 year after stem cell transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate 2 and 3 year after stem cell transplantation Progression free survival, overall survival, and adverse events. | — |
Countries
Japan
Contacts
Public ContactMotoshi Ichikawa
University of Tokyo Hospital Hematology and Oncology
Outcome results
None listed